Dasiglucagon acetate

Name: Dasiglucagon acetate
Brand: MedChemExpress
SKU: HY-P3469A
Rating: 4.5 (1 reviews)

Cat. No.: HY-P3469A Purity: 99.92%: Data Sheet
SDS

COA
Handling Instructions Technical Support

Solubility

In Vivo Dissolution Calculator

Dasiglucagon acetate is a human glucagon analog, and can increase plasma glucose. Dasiglucagon can be used in hypoglycemia research.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

Dasiglucagon acetate Chemical Structure

Size	Price	Stock	Quantity
5 mg	USD 230	In-stock	Estimated Time of Arrival: May 7
10 mg	USD 370	In-stock	Estimated Time of Arrival: May 7
25 mg	USD 740	In-stock	Estimated Time of Arrival: May 7
50 mg		Get quote
100 mg		Get quote

Get it by May 7 for select sizes. Order within 14 hrs 47 mins.

or Bulk Inquiry

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Dasiglucagon acetate:

Dasiglucagon Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Dasiglucagon acetate is a human glucagon analog, and can increase plasma glucose. Dasiglucagon can be used in hypoglycemia research^[1]^[2]^[3].

In Vivo

Dasiglucagon PK profile shows a dose-dependent and rapid increase in plasma levels^[2].

		Dasiglucagon dose
	0.1 mg	0.3 mg	0.6 mg	1.0 mg
N	5	16	16	16
AUC_0–30min (pmol*h/L)	99.4 (32.0)	302 (78.9)	444 (163)	884 (307)
AUC_0–360min (pmol*h/L)	451 (123)	1360 (166)	1630 (368)	4800 (697)
AUC_0–inf (pmol*h/L)	451 (123)	1360 (166)	2640 (365)	4810 (696)
C_max (pmol/L)	334 (113)	976 (208)	1570 (445)	2800 (767)
t_max (h)	0.50 (0.5-0.6)	0.63 (0.3-0.8)	0.58 (0.5-1.7)	0.63 (0.3-0.8)
t_1/2 (h)	0.43 (0.07)	0.43 (0.07)	0.49 (0.14)	0.54 (0.17)

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03688711	Zealand Pharma	Hypoglycemia\|Diabetes Mellitus, Type 1	November 1, 2018	Phase 3
NCT03735225	Zealand Pharma	Hypoglycemia	November 7, 2018	Phase 1
NCT02971228	Zealand Pharma\|Massachusetts General Hospital\|Beta Bionics, Inc.	Diabetes Mellitus, Type 1	November 2016	Phase 2
NCT03216226	Zealand Pharma\|SynteractHCR	Hypoglycemia\|Diabetes Mellitus, Type 1	June 28, 2017	Phase 3
NCT03667053	Zealand Pharma	Hypoglycemia	September 28, 2018	Phase 3
NCT05378672	Zealand Pharma	Hypoglycemia	February 2023	Phase 3
NCT03895697	Zealand Pharma	Hypoglycemia\|Diabetes Mellitus, Type 1	March 26, 2019	Phase 3
NCT03777176	Zealand Pharma	Congenital Hyperinsulinism	March 4, 2019	Phase 3
NCT04824872	Zealand Pharma	Hypoglycemia\|Glucose Metabolism Disorders	February 2023	Phase 2
NCT04836273	Filip Krag Knop\|Zealand Pharma\|University Hospital, Gentofte, Copenhagen	Hyperinsulinemic Hypoglycemia\|Postprandial Hypoglycemia	August 20, 2021	Phase 2
NCT04172441	Zealand Pharma	Congenital Hyperinsulinism	June 22, 2020	Phase 2\|Phase 3
NCT04764968	Steno Diabetes Center Copenhagen	Type 1 Diabetes\|Hypoglycemia	April 27, 2021	Phase 2
NCT04449692	Steno Diabetes Center Copenhagen	Type 1 Diabetes\|Hypoglycemia	July 2, 2020	Phase 2
NCT03941236	Zealand Pharma	Congenital Hyperinsulinism	May 1, 2019	Phase 3
NCT03378635	Zealand Pharma	Hypoglycemia\|Diabetes Mellitus, Type 1	December 7, 2017	Phase 3
NCT03840278	Massachusetts General Hospital\|Beta Bionics, Inc.\|Zealand Pharma	Type 1 Diabetes Mellitus	May 15, 2019	Phase 2\|Phase 3
NCT05454709	Inreda Diabetic B.V.	Diabetes Mellitus, Type 1	June 1, 2023	Phase 2
NCT02916251	Zealand Pharma	Diabetes Mellitus Type 1	December 1, 2016	Phase 2

Molecular Weight

3441.67

Formula

C₁₅₄H₂₂₆N₃₈O₅₂

Appearance

Solid

Color

White to off-white

Sequence Shortening

HSQGTFTSDYSKYLD{Aib}ARAEEFVKWLEST (acetate)

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture and light, under nitrogen

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

Solvent & Solubility

In Vitro:

H₂O : 16.67 mg/mL (4.84 mM; ultrasonic and adjust pH to 3 with HCl)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.2906 mL	1.4528 mL	2.9056 mL
5 mM	---	---	---
10 mM	---	---	---

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Purity & Documentation

Purity: 99.92%

Select Batch:

Data Sheet (270 KB) SDS (252 KB)

COA (243 KB)

Handling Instructions (2659 KB)

References

[1]. Bo Xu, et al. Dasiglucagon: an effective medicine for severe hypoglycemia. Eur J Clin Pharmacol. 2021 Dec;77(12):1783-1790. [Content Brief]

[2]. Ulrike Hövelmann, et al. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog. Diabetes Care. 2018 Mar;41(3):531-537. [Content Brief]

[3]. Yongjing Ju, et al. Dasiglucagon for treating severe hypoglycemia in patients with diabetes. Expert Rev Clin Pharmacol. 2022 Jul;15(7):799-803. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O

1 mM

0.2906 mL

1.4528 mL

2.9056 mL

7.2639 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.